Kamada Ltd (NASDAQ:KMDA) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 4, 2016
Zacks Investment Research has downgraded Kamada Ltd (NASDAQ:KMDA) to Sell in a statement released on 10/05/2016.
Boasting a price of $5.09, Kamada Ltd (NASDAQ:KMDA) traded 0.74% higher on the day. With the last stock price close up 24.61% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Kamada Ltd has recorded a 50-day average of $4.76 and a two hundred day average of $4.08. Volume of trade was down over the average, with 6,050 shares of KMDA changing hands under the typical 17,280
With a total market value of $0, Kamada Ltd has with a one year low of $3.26 and a one year high of $5.34 .
Brief Synopsis About Kamada Ltd (NASDAQ:KMDA)
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.